SUZHOU RIBO LIFE SCIENCE
Suzhou Ribo Life Science is a developer of RNA interference ( RNAi ) technology designed to treat liver diseases. The company's RNA interference ( RNAi ) technology is used to develop nucleic acid therapeutic drugs and related products, enabling healthcare providers to deliver more effective pharmaceuticals to patients.
SUZHOU RIBO LIFE SCIENCE
Social Links:
Industry:
Biotechnology Genetics Medical
Founded:
2007-01-01
Address:
Kunshan, Anhui, China
Country:
China
Website Url:
http://www.ribolia.com
Total Employee:
51+
Status:
Active
Contact:
86 512 5701 7802
Email Addresses:
[email protected]
Total Funding:
141.54 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Euro HSTS Mobile Non Scaleable Content Nginx Pound Sterling Japanese Yen
Similar Organizations
Beam Therapeutics
Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.
Foundation Medicine
Foundation medicine is a molecular information company developing clinical diagnostic tests that facilitates personalized cancer therapies.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Current Employees Featured
Founder
Investors List
FTZ Fund
FTZ Fund investment in Series C - Suzhou Ribo Life Science
SAIC Capital
SAIC Capital investment in Series C - Suzhou Ribo Life Science
China State-Owned Capital Venture Investment Fund
China State-Owned Capital Venture Investment Fund investment in Series C - Suzhou Ribo Life Science
Hillhouse Investment
Hillhouse Investment investment in Series C - Suzhou Ribo Life Science
Everest Ventures
Everest Ventures investment in Series C - Suzhou Ribo Life Science
GL Ventures LLC
GL Ventures LLC investment in Series C - Suzhou Ribo Life Science
CICC
CICC investment in Series C - Suzhou Ribo Life Science
Daxie Yungong Investment
Daxie Yungong Investment investment in Series C - Suzhou Ribo Life Science
Blue Ocean Capital Group
Blue Ocean Capital Group investment in Series C - Suzhou Ribo Life Science
Pan-Lin Capital
Pan-Lin Capital investment in Series C - Suzhou Ribo Life Science
Official Site Inspections
http://www.ribolia.com Semrush global rank: 5.65 M Semrush visits lastest month: 1.33 K
- Host name: 47.117.0.54
- IP address: 47.117.0.54
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "Suzhou Ribo Life Science"
Leadership Team-Suzhou Ribo Life Science Co., Ltd
Dr. Liang Zicai is the founding Chairman and CEO of Suzhou Ribo Life Science Co. Ltd. Dr. Liang Zicai was the main founder of Ribo in 2007. He is responsible for formulating the strategy for …See details»
苏州瑞博生物技术股份有限公司
瑞博生物专注于rna干扰（rnai）技术开发及小核酸药物产业化，是全球最早布局该领域的开拓者之一。 公司建立了自主可控、全技术链整合的小核酸药物研发平台，支持小核酸药物从早期研 …See details»
管理团队-苏州瑞博生物技术股份有限公司 - ribolia.com
梁子才博士现担任创始董事长、首席执行官。梁子才博士于2007年作为主要创始人创立瑞博生物。他主要负责公司的发展战略制定、小核酸创新技术的研发战略制定和实施、以及公司筹资事 …See details»
Suzhou Ribo Life Science Co., Ltd | LinkedIn
Established in 2007, Suzhou Ribo Life Science Co., Ltd. (Ribo) is a clinical stage company devoted to the development of innovative RNAi technologies and oligonucleotide therapeutics as an effort ...See details»
Suzhou Ribo Life Science - Crunchbase Company …
Organization. Suzhou Ribo Life Science . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. …See details»
Suzhou Ribo Life Science Co. Ltd. Information - RocketReach
Ribolia.com; Will Liu Director Of Business Development at Suzhou Ribo Life Science Co. Ltd. Beijing, China View. View Similar People. Related Companies China Meheco Corporation. 67 …See details»
Suzhou Ribo Life Science Co., Ltd. - synapse.zhihuiya.com
了解Suzhou Ribo Life Science Co., Ltd. (苏州瑞博生物技术股份有限公司)公司的药物管线，治疗领域，技术平台，以及它的19项临床试验, 564篇新闻和13篇文献，疾病领域:内分泌与代谢疾病，神经系统疾病，肿瘤，血液及淋巴系统疾 …See details»
苏州瑞博生物技术股份有限公司 - 苏州校园引才平台
联 系 人： 0512-57017856 联系电话： 0512-57017856 联系邮箱： [email protected] 单位地址： 江苏省苏州市昆山市玉山镇元丰路168号See details»
Suzhou Ribo Life Science Co., Ltd
Feb 25, 2018 Established in 2007, Suzhou Ribo Life Science Co. Ltd. is devoted to the advanced oligonucleotide therapeutics in China including siRNA, antisense and aptamer drugs …See details»
创新核酸药物增进人类健康福祉 - oa.ribolia.com
瑞博生物技术股份有限公司OA系统登录页面。See details»
Partnership for new liver disease treatments with Ribo | Boehringer ...
Jan 3, 2024 Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo) today announced a collaboration with Boehringer Ingelheim to develop novel treatments for …See details»
苏州瑞博生物技术股份有限公司 - 爱企查
爱企查为您提供苏州瑞博生物技术股份有限公司的企业信息查询服务，查询苏州瑞博生物技术股份有限公司工商注册信息、电话邮箱、公司地址、经营风险、控股持股、发展动态、财务状况、 …See details»
苏州瑞博生物技术股份有限公司核心团队_高管_核心人员 - 天眼查
天眼查为您提供苏州瑞博生物技术股份有限公司核心团队查询，包括公司创始人、ceo、cfo、coo等苏州瑞博生物技术股份有限公司核心高管人员信息，让您能够快速了解其公司核心团 …See details»
Ribo partners with Boehringer Ingelheim to develop new …
Jan 3, 2024 Mölndal, Sweden, Kunshan, China and Ingelheim, Germany – 3 January 2024 Suzhou Ribo Life Science Co. Ltd. and Ribocure Pharmaceuticals AB (Ribo) today announced …See details»
公司介绍-苏州瑞博生物技术股份有限公司 - ribolia.com
瑞博生物成立于2007年，是一家致力于开发rna干扰（rnai）药物的创新型研发企业，是中国小核酸技术和小核酸制药产业的主要 ...See details»
瑞博生物_苏州瑞博生物技术股份有限公司_亿欧数据
亿欧数据为您提供苏州瑞博生物技术股份有限公司的主营业务、公司简介、企业官网、公司地址、招聘信息、财务信息、融资情况、团队信息、电话号码、招投标信息、专利等多维度详细信息 …See details»
瑞博生物-动脉网 - vbdata.cn
Jan 18, 2007 [email protected] 瑞博生物成立于2007年，是一家致力于开发RNA干扰（RNAi）药物的创新型研发企业，是中国小核酸技术和小核酸制药产业的主要开拓者。 公司的研究与开 …See details»
First Milestone Successfully Achieved in Ribo’s Collaboration in …
Jan 10, 2025 These achievements highlight the strength of Boehringer Ingelheim's expertise in MASH and validates the power of the Ribo platform and organization (click to view original …See details»
苏州瑞博生物技术有限公司：官网、创业项目及相关资讯 - VCNEWS
苏州瑞博生物技术有限公司（简称“瑞博”）是致力于开发rna干扰技术的创新型药物研发企业，是中国小核酸技术和小核酸制药的主要开拓者。 公司自成立以来，围绕小核酸药物开发的特点在 …See details»
Overview-Suzhou Ribo Life Science Co., Ltd
In Mar. 2020, Ribo closed its 470M RMB Series C2 financing, led by China Venture Capital Fund, co-led by CICC Qide Fund and GL Ventures, and co-invested by Hengxu Capital, Everest VC, …See details»